Contribution of Deletion in Angiotensin-converting Enzyme But Not A1166C Angiotensin II Type-1 Receptor Gene Polymorphisms to Clinical Outcomes in Atherothrombotic Disease

Archives of Medical Research

Volumn 42, Issue 3, 2011, Pages 202-210

  Le Hello, Claire ^a   Fradin, Sabine ^a   Morello, Rémy ^a   Coffin, Olivier ^a   Maïza, Dominique ^a   Hamon, Martial ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Atherothrombosis; Cohort follow up; Genetic polymorphisms; Renin angiotensin system

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; ATHEROTHROMBOTIC DISEASE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CREATININE CLEARANCE; DNA POLYMORPHISM; DYSLIPIDEMIA; FEMALE; GENOTYPE; HEMOGLOBIN BLOOD LEVEL; HUMAN; ISCHEMIA; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LIPOPROTEIN BLOOD LEVEL; MAJOR ADVERSE CARDIOVASCULAR EVENT; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MORTALITY; OBSERVATIONAL STUDY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; REVASCULARIZATION; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE;

AGED; AORTIC DISEASES; ARTERIAL OCCLUSIVE DISEASES; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; INDEL MUTATION; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIDYL-DIPEPTIDASE A; PERIPHERAL ARTERIAL DISEASE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECEPTOR, ANGIOTENSIN, TYPE 1; VASCULAR DISEASES; VASCULAR GRAFTING;

EID: 79959702724     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2011.05.003     Document Type: Article

References (31)

1. Arnett D.K., Baird A.E., Barkley R.A., et al. Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 2007, 115:2878-2901.
2. Völzke H., Engel J., Kleine V., et al. Angiotensin I-converting enzyme insertion/deletion polymorphism and cardiac mortality and morbidity after coronary artery bypass graft surgery. Chest 2002, 122:31-36.
3. Palmer B.R., Pilbrow A.P., Yandle T.G., et al. Angiotensin-converting enzyme gene polymorphism interacts with left ventricular ejection fraction and brain natriuretic peptide levels to predict mortality after myocardial infarction. J Am Coll Cardiol 2003, 41:729-736.
4. Hamon M., Bauters C., Amant C., et al. Relation between the deletion polymorphism of the angiotensin-converting enzyme gene and late luminal narrowing after coronary angioplasty. Circulation 1995, 92:296-299.
5. Andrikopoulos G.K., Richter D.J., Needham E.W., et al. The paradoxical association of common polymorphisms of the renin-angiotensin system genes with risk of myocardial infarction. Eur J Cardiovasc Prev Rehabil 2004, 11:477-483.
6. Anand S.S., Xie C., Paré G., et al. Genetic variants associated with myocardial infarction risk factors in over 8000 individuals from five ethnic groups: the INTERHEART Genetics Study. Circ Cardiovasc Genet 2009, 2:16-25.
7. Gardemann A., Nguyen Q.D., Humme J., et al. Angiotensin II type 1 receptor A1166C gene polymorphism. Absence of an association with the risk of coronary artery disease and myocardial infarction and of a synergistic effect with angiotensin-converting enzyme gene polymorphism on the risk of these diseases. Eur Heart J 1998, 19:1657-1665.
8. Wijpkema J.S., van Haelst P.L., Monraats P.S., et al. Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1. Pharmacogenet Genomics 2006, 16:331-337.
9. van Geel P.P., Pinto Y.M., Zwinderman A.H., et al. Increased risk for ischaemic events is related to combined RAS polymorphism. Heart 2001, 85:458-462.
10. Filippi-Codaccioni E., Morello R., Fradin S., et al. Relation between the A1166C angiotensin II type 1 receptor gene polymorphism and cardiovascular outcomes after myocardial infarction. EuroIntervention 2005, 1:38-42.
11. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215.
12. Rigat B., Hubert C., Alhenc-Gelas F., et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990, 86:1343-1346.
13. Shanmugam V., Sell K.W., Saha B.K. Mistyping ACE heterozygotes. PCR Methods Appl 1993, 3:120-121.
14. Furuta H., Guo D.F., Inagami T. Molecular cloning and sequencing of the gene encoding human angiotensin II type 1 receptor. Biochem Biophys Res Commun 1992, 183:8-13.
15. Takayanagi R., Ohnaka K., Sakai Y., et al. Molecular cloning, sequence analysis and expression of a cDNA encoding human type-1 angiotensin II receptor. Biochem Biophys Res Commun 1992, 183:910-916.
16. Sayed-Tabatabaei F.A., Oostra B.A., Isaacs A., et al. ACE polymorphisms. Circ Res 2006, 98:1123-1133.
17. Dzau V.J. Tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 2001, 37:1047-1052.
18. van der Knaap R., Siemes C., Coebergh J.W., et al. Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study. Cancer 2008, 112:748-757.
19. Cambou J.P., Aboyans V., Constans J., et al. Characteristics and outcome of patients hospitalised for lower extremity peripheral artery disease in France: the COPART Registry. Eur J Vasc Endovasc Surg 2010, 39:577-585.
20. Alberts M.J., Bhatt D.L., Mas J.L., et al. Three-year follow-up and event rates in the International Reduction of Atherothrombosis for Continued Health Registry. Eur Heart J 2009, 30:2318-2326.
21. Saltzberg S.S., Pomposelli F.B., Belfield A.K., et al. Outcome of lower-extremity revascularization in patients younger than 40 years in a predominantly diabetic population. J Vasc Surg 2003, 38:1056-1059.
22. Feringa H.H., Vidakovic R., Karagiannis S.E., et al. Impaired glucose regulation, elevated glycated haemoglobin and cardiac ischaemic events in vascular surgery patients. Diabet Med 2008, 25:314-319.
23. Halkos M.E., Lattouf O.M., Puskas J.D., et al. Elevated preoperative hemoglobin A1c level is associated with reduced long-term survival after coronary artery bypass surgery. Ann Thorac Surg 2008, 86:1431-1437.
24. Davenport D.L., Xenos E.S., Hosokawa P., et al. The influence of body mass index obesity status on vascular surgery 30 day morbidity and mortality. J Vasc Surg 2009, 49:140-147.
25. Lancefield T., Clark D.J., Andrianopoulos N., et al. Is there an obesity paradox after percutaneous coronary intervention in the contemporary era? An analysis from a multicenter Australian registry. JACC Cardiovasc Interv 2010, 3:660-668.
26. Momary K.M., Dorsch M.P., Bates E.R. Genetic causes of clopidogrel nonresponsiveness: which ones really count?. Pharmacotherapy 2010, 30:265-274.
27. Hulot J.S., Collet J.P., Silvain J., et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010, 56:134-143.
28. Baigent C., Keech A., Kearney P.M., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
29. Smeeth L., Douglas I., Hall A.J., et al. Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 2009, 67:99-109.
30. Mehta R.H., Hafley G.E., Gibson C.M., et al. Influence of preoperative renal dysfunction on one-year bypass graft patency and two-year outcomes in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 2008, 136:1149-1155.
31. van Straten A.H., Soliman Hamad M.A., van Zundert A.A., et al. Preoperative renal function as a predictor of survival after coronary artery bypass grafting: comparison with a matched general population. J Thorac Cardiovasc Surg 2009, 138:971-976.